Astroglial Cells: Emerging Therapeutic Targets in the Management of Traumatic Brain Injury

Cells. 2024 Jan 12;13(2):148. doi: 10.3390/cells13020148.

Abstract

Traumatic Brain Injury (TBI) represents a significant health concern, necessitating advanced therapeutic interventions. This detailed review explores the critical roles of astrocytes, key cellular constituents of the central nervous system (CNS), in both the pathophysiology and possible rehabilitation of TBI. Following injury, astrocytes exhibit reactive transformations, differentiating into pro-inflammatory (A1) and neuroprotective (A2) phenotypes. This paper elucidates the interactions of astrocytes with neurons, their role in neuroinflammation, and the potential for their therapeutic exploitation. Emphasized strategies encompass the utilization of endocannabinoid and calcium signaling pathways, hormone-based treatments like 17β-estradiol, biological therapies employing anti-HBGB1 monoclonal antibodies, gene therapy targeting Connexin 43, and the innovative technique of astrocyte transplantation as a means to repair damaged neural tissues.

Keywords: astrocytes; astroglia; traumatic brain injury.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal
  • Astrocytes
  • Brain Injuries, Traumatic* / therapy
  • Central Nervous System
  • Humans
  • Medicine*

Substances

  • Antibodies, Monoclonal

Grants and funding

The APC was funded by account sources of Medical University of Lublin.